the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Ovary/Fallopian Tube/Primary Peritoneal Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
CIRB17-0986 Moroney, John NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab (IND # ) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer—Safety Lead-in Portion Details
12-2044 Moroney, John GOG 225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Details
Phase II
Study No PI Title
CIRB17-0986 Moroney, John NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab (IND # ) versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer—Safety Lead-in Portion Details
IRB16-1602 Yamada, S. Diane Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus Six Cycles of IV Carboplatin and Paclitaxel in Patients with Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Undergoing Second Cytoreductive Surgery Details
IRB16-1368 Fleming, Gini An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer Details
IRB16-0574 Fleming, Gini Phase I/II Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer Details
IRB16-1194 Fleming, Gini A Randomized, Placebo-controlled, Double- blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients with Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment with a Safety Lead-in Details
CIRB16-1022 Moroney, John NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Details
CIRB15-1357 Sharma, Manish EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-0334 Fleming, Gini A Phase II, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Details
IRB13-1235 Yamada, S. Diane A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube & Primary Peritoneal Cancer Details
10-726-A Moroney, John GOG 264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Details
Phase I
Study No PI Title
IRB16-1583 Fleming, Gini A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer (SCRX003-001) Details
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies Details
IRB16-0574 Fleming, Gini Phase I/II Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer Details
IRB16-1194 Fleming, Gini A Randomized, Placebo-controlled, Double- blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients with Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment with a Safety Lead-in Details
IRB16-0417 Kindler, Hedy A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination with the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors Details
CIRB16-1022 Moroney, John NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1024 Luke, Jason A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors Details
IRB15-0396 Fleming, Gini A Phase Ib Study of The Safety and Pharmacology of MPDL3280A Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors Details
Others
Study No PI Title
IRB16-0606 Romero, Iris Stand Up To Cancer: WISP Trial (Women Choosing Surgical Prevention) Details
IRB16-0402 Nakamura, Yusuke Identification and Validation of Neoantigens Using Peripheral Blood Collected From Ovarian Cancer Patients


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .